SCHEMBL1007245

SCHEMBL1007245

COC(=O)c1c(NC(=O)c2ccc(OCCn3nc(C(F)(F)F)c4c3CCCC4)cc2)sc(C(N)=O)c1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
FLT3 P36888 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 3/20 0.43
POLB P06746 3/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 7/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007833 0.88 GRIN2C (0.46) ALDH1A1FLT3SMN1; SMN2TSHRTP53
SCHEMBL1009404 0.81 SMN1; SMN2 (0.55) ALDH1A1KDM4ENPSR1SMN1; SMN2TSHR
SCHEMBL1893597 0.79 MAPT (0.51) ALDH1A1NPSR1SMN1; SMN2TSHRPOLB
SCHEMBL1006589 0.79 TP53 (0.42) ALDH1A1KDM4ENPSR1RXFP1SMN1; SMN2
SCHEMBL12674197 0.78 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2TSHRPOLBTP53
SCHEMBL1009492 0.78 MAPT (0.50) ALDH1A1SMN1; SMN2TSHRPOLBTP53
SCHEMBL1007223 0.77 MAPT (0.53) ALDH1A1NPSR1SMN1; SMN2TSHRPOLB
SCHEMBL1007326 0.77 MAPT (0.49) SMN1; SMN2TSHRPOLBTP53MAPT
SCHEMBL1005566 0.76 SMN1; SMN2 (0.44) SMN1; SMN2TSHRPOLBTP53MAPT
SCHEMBL12666826 0.76 RAB9A (0.46) ALDH1A1NPSR1SMN1; SMN2TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885KDM4E 3157/4885NPSR1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.